Skip to main content

IPO Chilli Ratings

IPO Chilli Ratings
Click to understand how it works

Featured

Singapore Institute of Advanced Medicine Holdings Ltd

Singapore Institute of Advanced Medicine Holdings Ltd ("Sam" or the "Company") is offering 114m new shares comprising 4.415m Public Offer Shares and 109.585m Placement Shares at $0.23 each for a listing on Catalist.  The Company aims to raise $26.2m and the majority of the proceeds will be used to repay debt and the balance for working capital. The market cap based on the IPO price is $231.8m and the offer will close on 14 Feb at 12 noon and starts trading on 16 Feb 2024 at 9am.   Principal Business SAM is a healthcare service provider using advanced technology for early and accurate diagnosis to detect and treat cancer, neurodegenerative and cardiovascular diseases.  SAM has strategic collaborations with public and private institutions for research and clinical work.  SAM's goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer and is one of the first to adopt proto beam therapy treatment in Singapore. Fi

QT Vascular - Placement results

The placement results for QT Vascular throw up an interesting surprise.

In addition to the substantial shareholders who continue to support the company such as EDB and Johnson and Johnson, there is a new shareholder just below 5%, Asdew.

Asdew Acquisition - Alan Wang took a very substantial stake in the Company. He is the same person behind very Hankore placement before it more than doubled from 5c.

There is another investor called Havenport which I have previously blog about, founded by the team at Legg Mason.

Let's see if the 2 new substantial shareholders can perform some magic to the counter.

Comments

Are this placement results regularly updated or it tool more than a week for you to post something about this.